Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?

Détails

Ressource 1Télécharger: 28829211_postprint.pdf (1326.93 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_243D1EA3FB5F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?
Périodique
Expert opinion on therapeutic targets
Auteur⸱e⸱s
Juillerat-Jeanneret L., Tafelmeyer P., Golshayan D.
ISSN
1744-7631 (Electronic)
ISSN-L
1472-8222
Statut éditorial
Publié
Date de publication
10/2017
Peer-reviewed
Oui
Volume
21
Numéro
10
Pages
977-991
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Fibroblast activation protein-α (FAP-α) belongs to the family of prolyl-specific serine proteases. FAP-α displays both exopeptidase and endopeptidase/gelatinase/collagenase activities. FAP-α protein and/or activity have been associated with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues. FAP-α is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders associated with fibrotic dysregulation. Areas covered: In this review, we summarize the mechanisms driving tissue fibrosis and describe some of the enzymes involved in fibrosis, concentrating on FAP-α. We describe its enzymatic properties, discuss the tools developed to control its activity and the problem of selectivity toward the other proteases of the family and outline its potential biological substrates. We also consider non-enzymatic functions of this protein and suggest that repression of FAP-α expression may represent therapeutic options. Expert opinion: Questions remain regarding the biological functions of FAP-α, either dependent or independent of its enzyme activity. However, as progress is underway to develop FAP-α-specific inhibitors and therapeutic antibodies, its role in diseases associated with fibrosis is starting to emerge, ultimately leading to novel therapeutic options for inflammatory and oncologic diseases.

Mots-clé
Animals, Disease Progression, Drug Design, Fibroblasts/metabolism, Fibrosis/drug therapy, Fibrosis/pathology, Gelatinases/antagonists & inhibitors, Gelatinases/genetics, Gelatinases/metabolism, Gene Expression Regulation, Humans, Membrane Proteins/antagonists & inhibitors, Membrane Proteins/genetics, Membrane Proteins/metabolism, Molecular Targeted Therapy, Neoplasms/drug therapy, Neoplasms/pathology, Serine Endopeptidases/genetics, Serine Endopeptidases/metabolism, Cancer, FAP-α, fibroblast activation protein -α, fibrosis, inflammation, inhibitors, therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/09/2017 14:20
Dernière modification de la notice
20/08/2019 14:02
Données d'usage